 |
|
COMMENTS & OPINIONS
Interleukin 2 and HIV RNA Levels—Reply
Richard B. Pollard, MD; for the AIDS Clinical Trials Group 328 Team
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
The authors of the accompanying letter question whether interleukin 2 treatment could have increased viral replication and loss of initial virologic control resulting from antiretroviral therapy. The data presented in Figure 4 of our article showed that there were no differences in viral load at week 60 and 84 by treatment arm.1
In addition, the protocol specified that changes in antiretroviral regimens were allowed if viral load increased by greater than 0.7 log RNA copies that was documented on 2 separate occasions at least 1 week apart. Only 1 patient receiving interleukin 2 therapy had his highly active antiretroviral therapy (HAART) regimen changed (at week 60) because he met this criterion; no other patients had their HAART regimen changed for this reason at any time between week 12 and week 24.
Finally, real-time viral loads were . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Interleukin 2 and HIV RNA Levels
Roderick Go and Roy Steigbigel
Arch Intern Med. 2007;167(19):2144-2145.
EXTRACT
| FULL TEXT
RELATED ARTICLE
The Virologic, Immunologic, and Clinical Effects of Interleukin 2 With Potent Antiretroviral Therapy in Patients With Moderately Advanced Human Immunodeficiency Virus Infection: A Randomized Controlled Clinical Trial—AIDS Clinical Trials Group 328
Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, Alan Landay, John Fahey, Richard Reichman, Alejo Erice, R. Pat Bucy, J. Michael Kilby, Michael M. Lederman, Carol D. Hamilton, Juan Lertora, Becky L. White, Pablo Tebas, Anne-Marie Duliege, Richard B. Pollard, and for the AIDS Clinical Trials Group 328 Study Team
Arch Intern Med. 2007;167(6):597-605.
ABSTRACT
| FULL TEXT
|
